This is an aggregated industry headline. Read the full story at Endpoints News →
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-quarter earnings call ...
By Endpoints News
· May 12, 2026
· via Endpoints News
Image: Endpoints News
Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
DealsFierceBiotech ↗
Novo Nordisk has found the latest buyer for one of its orphaned cell therapies.…
DealsBriefing
Bristol Myers Squibb will pay $600M upfront in a $15.2B collaboration with Hengrui, aiming to leverage China’s…
DealsBioPharma Dive ↗
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…